KR20240004584A - 탈유비퀴티나아제-표적화 키메라 및 관련된 방법 - Google Patents

탈유비퀴티나아제-표적화 키메라 및 관련된 방법 Download PDF

Info

Publication number
KR20240004584A
KR20240004584A KR1020237040245A KR20237040245A KR20240004584A KR 20240004584 A KR20240004584 A KR 20240004584A KR 1020237040245 A KR1020237040245 A KR 1020237040245A KR 20237040245 A KR20237040245 A KR 20237040245A KR 20240004584 A KR20240004584 A KR 20240004584A
Authority
KR
South Korea
Prior art keywords
hydrate
pharmaceutically acceptable
solvate
stereoisomer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237040245A
Other languages
English (en)
Korean (ko)
Inventor
라이디아 보이케
더스틴 리어드 도발라
나타니엘 제임스 헤닝
매튜 제임스 헤쎄
강 리우
제프리 엠. 맥켄나
다니엘 케이. 노무라
마르쿠스 에버하드 쉴레
제시카 니콜 스프래들린
존 에이. 탈라리코
칼 씨. 워드
멜리사 피게띠
Original Assignee
노파르티스 아게
더 리전트 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게, 더 리전트 오브 더 유니버시티 오브 캘리포니아 filed Critical 노파르티스 아게
Publication of KR20240004584A publication Critical patent/KR20240004584A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237040245A 2021-04-29 2022-04-29 탈유비퀴티나아제-표적화 키메라 및 관련된 방법 Pending KR20240004584A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163181796P 2021-04-29 2021-04-29
US63/181,796 2021-04-29
US202163186739P 2021-05-10 2021-05-10
US63/186,739 2021-05-10
US202163273118P 2021-10-28 2021-10-28
US63/273,118 2021-10-28
US202263311781P 2022-02-18 2022-02-18
US63/311,781 2022-02-18
PCT/US2022/027120 WO2022232634A1 (en) 2021-04-29 2022-04-29 Deubiquitinase-targeting chimeras and related methods

Publications (1)

Publication Number Publication Date
KR20240004584A true KR20240004584A (ko) 2024-01-11

Family

ID=81748638

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237040245A Pending KR20240004584A (ko) 2021-04-29 2022-04-29 탈유비퀴티나아제-표적화 키메라 및 관련된 방법

Country Status (11)

Country Link
US (1) US20240252655A1 (enExample)
EP (1) EP4329815A1 (enExample)
JP (1) JP2024515828A (enExample)
KR (1) KR20240004584A (enExample)
CN (1) CN120225225A (enExample)
AU (1) AU2022265718A1 (enExample)
BR (1) BR112023022315A2 (enExample)
CA (1) CA3216614A1 (enExample)
IL (1) IL307863A (enExample)
MX (1) MX2023012852A (enExample)
WO (1) WO2022232634A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024220874A2 (en) * 2023-04-21 2024-10-24 Icahn School Of Medicine At Mount Sinai Otub1 small-molecule binders and otub1-recruiting deubiquitinase-targeting chimeras (dubtacs)
WO2024233280A1 (en) * 2023-05-05 2024-11-14 Icahn School Of Medicine At Mount Sinai Heterobifunctional small molecules that deubiquitinylate and stabilize target proteins by recruiting usp7
WO2024264072A2 (en) * 2023-06-23 2024-12-26 Stablix, Inc. Parp inhibitors
CN119350422B (zh) * 2024-12-25 2025-04-04 中国药科大学 一种去泛素化酶靶向嵌合体化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008109031A (ru) 2005-08-11 2009-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы муковисцидозного трансмембранного регулятора проводимости
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
PL2168966T3 (pl) 2007-06-15 2017-06-30 Msd K.K. Pochodna bicykloaniliny
CN102743385B (zh) * 2007-11-16 2014-09-17 沃泰克斯药物股份有限公司 Atp结合盒转运蛋白的异喹啉调节剂
US20110035601A1 (en) 2007-12-21 2011-02-10 University Of Virginia Patent Foundation System, method and computer program product for protecting software via continuous anti-tampering and obfuscation transforms
EP2303885B1 (en) 2008-06-12 2013-07-03 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
CZ2009620A3 (cs) 2009-09-22 2011-04-06 Ústav makromolekulární chemie AV CR, v.v.i. Surovina pro výrobu polyurethanu a zpusob její výroby z odpadního polyurethanu
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2011133953A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
KR20150097660A (ko) 2012-12-19 2015-08-26 노파르티스 아게 Cftr 채널을 억제하기 위한 트리시클릭 화합물
CA2895656A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
WO2018037350A1 (en) 2016-08-23 2018-03-01 Laurus Labs Limited Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof
CA3103205A1 (en) * 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting uchl5
WO2020069105A1 (en) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degraders of wee1 kinase
AU2020224327B2 (en) * 2019-02-21 2022-09-29 Entact Bio Limited Survival-targeting chimeric ( SURTAC) molecules
EP4090371A4 (en) * 2020-01-14 2024-04-03 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY RE-ROUTING ENDOGENOUS DEUBIQUITINASES

Also Published As

Publication number Publication date
EP4329815A1 (en) 2024-03-06
CA3216614A1 (en) 2022-11-03
CN120225225A (zh) 2025-06-27
MX2023012852A (es) 2024-01-15
US20240252655A1 (en) 2024-08-01
WO2022232634A1 (en) 2022-11-03
JP2024515828A (ja) 2024-04-10
BR112023022315A2 (pt) 2024-02-20
IL307863A (en) 2023-12-01
AU2022265718A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
US20240252655A1 (en) Deubiquitinase-targeting chimeras and related methods
RU2687060C2 (ru) Фармацевтические соединения
WO2024067744A1 (zh) 杂环取代喹唑啉及其制备方法和应用
EP4006024A1 (en) Heterocyclic amide compound, preparation method therefor and use thereof
EP3398950A1 (en) Novel kinase inhibitor against wild-type egfr and mutated egfr
CA3029086C (en) Chiral heterocyclic compound with hedgehog pathway antagonist activity, method and use thereof
WO2025021075A1 (zh) 一类nsd蛋白降解剂及其用途
KR20230144529A (ko) 키나아제 억제제 및 이의 용도
EP3932915A1 (en) Acryloyl-containing nuclear transport regulator and uses thereof
WO2023129564A9 (en) Degraders of grk2 and uses thereof
WO2023131677A1 (en) Compounds containing a hydroxyphenyl moiety and their use
CN118772048B (zh) 一种hdac抑制剂及其用途
EP3805203A1 (en) Azetidine derivative, and prodrug thereof
EP4538268A1 (en) Pyridazin-3-carboxamide compound as tyk2 inhibitor
KR20250069999A (ko) Tyk2 억제제로서의 치환된 피리다진-3-카르복스아미드 화합물
US20250188062A1 (en) Triazine compounds and methods of making and using the same
EP4556465A1 (en) Novel bicyclic pd-l1 inhibitors, preparation methods therefor and medicinal uses thereof
EP4631931A1 (en) Hdac inhibitor and use thereof
EP4356909A1 (en) 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides derivatives and use thereof
WO2024097355A1 (en) Deubiquitinase-targeting chimeras and related methods
US20250066353A1 (en) Vanin-1 inhibitors
Calder et al. The Design, Synthesis, and Evaluation of Hypoxia-Activated Prodrugs of the KDAC Inhibitor Panobinostat
KR20260028105A (ko) 자가면역 질환의 치료를 위한 소분자
EP4653442A1 (en) Polycyclic compound for treating neurological diseases and tumors
CN122055172A (zh) 靶向质子感应受体gpr4的嵌合放射性药物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250429

Comment text: Request for Examination of Application